Severe acute respiratory syndrome, a pathological immune response to the new coronavirus - Implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology

Viral Immunology

Volumn 17, Issue 4, 2004, Pages 535-544

  Bermejo, Jesus F ^a   Muñoz Fernandez, M Angeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; EFAVIRENZ; ETANERCEPT; IMMUNOMODULATING AGENT; INDINAVIR; INFLIXIMAB; KETOTIFEN; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEDOCROMIL SODIUM; OXYGEN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; RITONAVIR; ROLIPRAM; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; TENOFOVIR; THEOPHYLLINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ARTERIAL OXYGEN SATURATION; AUTOIMMUNE DISEASE; CANCER; CELL DAMAGE; CHILDHOOD DISEASE; DISEASE TRANSMISSION; DIZZINESS; DRUG DESIGN; EPIDEMIOLOGICAL DATA; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NAUSEA; NONHUMAN; PROGNOSIS; RESPIRATORY DISTRESS; RESPIRATORY FUNCTION; REVIEW; RISK FACTOR; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; STOMACH DISEASE; SYMPTOMATOLOGY; VACCINE PRODUCTION; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS; VOMITING;

CORONAVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES; SARS CORONAVIRUS;

EID: 11144221320     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2004.17.535     Document Type: Review

References (57)

1. Andre, P., M. Groettrup, P. Klenerman, et al. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. USA 95:13120-4.
2. Beijing Group of National Research Project for SARS. 2003. Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin. Med. J. (Engl.) 116:1283-7.
3. Bermejo, M.J.F., J.L. Jiménez, and M.A. Muñoz- Fernández. 2003. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Med. Sci. Monit. 9:SR29-34.
4. Bermejo, J.F., and M.A. Muñoz-Fernández. 2004. Severe acute respiratory syndrom in children: a clue to better understanding the disease and advance towards solutions. Acta Paediatr. 93:856-7.
5. Bitnun, A., U. Allen, H. Heurter, et al. 2003. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. Paediatrics 112:e261.
6. Bruynzeel, I., T.J. Stoof, and R. Willemze. 1998. Pentoxifylline and skin inflammation. Clin. Exp. Dermatol. 23:168-172.
7. Chen, X.P., and Y. Cao. 2004. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome. Clin. Infect. Dis. 38:1030-2.
8. Chiu, W.K., P.C. Cheung, K.L. Ng, et al. 2003. Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong. Pediatr. Crit. Care Med. 4:279-83.
9. Chu, C.M., V.C. Cheng, I.F. Hung, et al. 2004. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252-6.
10. Cinatl, J., B. Morgenstern, G. Bauer, et al. 2003. Treatment of SARS with human interferons. Lancet 362:293-4.
11. Clarke, T. 2003. SARS spares kids [On-line]. Available: www.nature.com/nsu/030915/030915-1.html.
12. Duan, Z.P., Y. Chen, J. Zhang, et al. 2003. Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome [Chinese]. Zhonghua Gan Zang Bing Za Zhi. 11:493-495.
13. Fouchier, R.A.M., T. Kuiken, M. Schutten, et al. 2003. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423:240.
14. Fowler, R.A., S.E. Lapinsky, D. Hallett, et al. 2003. Critically ill patients with severe acute respiratory syndrome. JAMA 290:367-73.
15. Fujii, T., T. Nakamura, and A. Iwamoto. 2004. Current concepts in SARS treatment. J. Infect. Chemother. 10:1-7.
16. Giembycz, M.A. 2002. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest Dis. 57:48-64.
17. Gomez, J., D. García-Domingo, C. Martínez-A, et al. 1997. Role of Nf-kb in the control of apoptotic and proliferative responses in IL-2-responsive T cells. Front. Biosci. 2:49-60.
18. Goodbourn, S., L. Didcock, R.E. Randall. 2000. Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures [On-line]. Avalaible: www.soc genmicrobiol.org.uk/JGVDirect/17157/17157 ft.htm.
19. GuanFu, J., and W. ZhongYuan. 2004. Is serum in childhood naturally protective against SARS-coronavirus? Immunol. Lett. 94:161-162.
20. Haagmans, B.L., T. Kuiken, B.E. Martina, et al. 2004. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 10:290-3.
21. Haddad, J.J., S.C. Land, W.O. Tarnow-Mordi, et al. 2002. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. JPET 300:559-566.
22. Hon, K.L., C.W. Leung, W.T. Cheng, et al. 2003. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 361:1701-3.
23. Jimenez, J.L., C. Punzón, J. Navarro, et al. 2001. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther. 299:753-759.
24. Karras, A., and O. Hermine. 2002. Hemophagocytic syndrome [French]. Rev. Med. Interne. 23:768-78.
25. Kelvin, D.J. 2004. Immune responses in patients with severe acute respiratory syndrome (SARS): lessons from cytokine and gene expression profiling, FACS analysis, and epitope mapping. Presented at the International Conference on SARS, Lübeck, Germany.
26. Khanna, D., M. McMahon, and D.E. Furst. 2004. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 27:307-24.
27. Krakauer, T. 1999. Induction of CC chemokines in human peripheral blood mononuclear cells by staphylococcal exotoxins and its prevention by pentoxifylline. J. Leukoc. Biol. 66:158-64.
28. Krakauer, T. 2000. Pentoxifylline inhibits ICAM-1 expression and chemokine production induced by proinflammatory cytokines in human pulmonary epithelial cells. Immunopharmacology 46:253-61.
29. Krakauer, T., and B.G. Stiles. 1999. Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release. Clin. Diagn. Lab. Immunol. 6:594-8.
30. Kuiken, T., R.A. Fourchier, M. Schutten, et al. 2003. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362:263-70.
31. Leung, C.W., Y.W. Kwan, P.W. Ko, et al. 2004. Severe acute respiratory syndrome among children. Pediatrics 113:e535-43.
32. Li, C.S., and S.F. Pan. 2003. Analysis and causation discussion of 185 severe acute respiratory syndrome dead cases. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 15:582-4.
33. Li, L.H., Y.L. Shi, P. Li, et al. 2003. Detection and analysis of SARS coronavirus-specific antibodies in sera from non-SARS children. Di Yi Jun Yi Da Xue Xue Bao 23:1085-7.
34. Liu, J.H. 2003. Anti-SARS activity only existed in 2% of the children's serum samples [On-line]. Available: www.people.com.cn.
35. Marshall, E., and M. Enserink. 2004. Caution urged on SARS vaccines. Science 303:944-946.
36. Martina, B.E., B.L. Haagmans, and T. Kuiken. 2003. Virology: SARS virus infection of cats and ferrets. Nature 425:915.
37. Monini, P., C. Sgadari, G. Barillari, et al. 2003. HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity J. Antimicrob. Chemother. 51:207-211.
38. Navarro, J., M.C. Punzon, A. Pizarro, et al. 1996. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. AIDS 10:469-75.
39. Navas-Martin, S., and S.R. Weiss. 2003. SARS: lessons learned from other coronaviruses. Viral Immunol. 16:461-474.
40. Neuner, P., G. Klosner, M. Pourmojib, et al. 1994. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83:262-7.
41. Ng, M.H., K.M Lau, L. Li, et al. 2004. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J. Infect. Dis. 190:515-8.
42. Nicholls, J.M., L.L.M. Poon, K.C. Lee, et al. 2003. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361:9370. Available: Http://image.thelancet.com/ extras /03art4347web.pdf.
43. Openshaw, P.J.M. 2004. What does the peripheral blood tell you in SARS? Clin. Exp. Immunol. 136:11.
44. Pati, S., C.B. Pelser, J. Dufraine, et al. 2002. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99:3771-9.
45. Peiris, J.S., C.M. Chu, and V.C. Cheng. 2003. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361:1767-72.
46. Stoof, T.J., E.N. van de Brink, R. Willemze, et al. 1994. Pentoxifylline (PTX) inhibits interferon-g (IFN-g) induced IP-10 mRNA expression on cultured human keratinocytes (KC). J. Invest. Dermatol. 103:442A.
47. Sullivan, G.W., H.T. Carper, W.J. Novick, et al. 1988. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect. Immun. July:1722-1729.
48. Tan, E.L., E.E. Ooi, C.Y. Lin, et al. 2004. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 10:581-6.
49. Tong, Z., H. Dai, B. Chen, et al. 2003. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 124:1526-32.
50. Tsou, I.Y., L.E. Loh, G.J. Kaw, et al. 2004. Severe acute respiratory syndrome (SARS) in a paediatric cluster in Singapore. Pediatr. Radiol. 34:43-6.
51. Tovo, P.A. 2000. Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects. AIDS 14:743-744.
52. Wong A.T., O.T. Tsang, M.Y. Wong, et al. 2004. Coronavirus infection in an AIDS patient. AIDS 18:829-30.
53. Wong, C.K., C.W. Lam, and A.K. Wu. 2004. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136:95-103.
54. Wong, G.W., A.M. Li, P.C. Ng, et al. 2003. Severe acute respiratory syndrome in children. Pediatr. Pulmonol. 36:261-6.
55. Wong, R.S., A. Wu, K.F. To, et al. 2003. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 21:1358-62.
56. Xie, J., Y. Han, T.S. Li, et al. 2003. Dynamic changes of plasma cytokine levels in patients with severe acute respiratory syndrome [Chinese]. Zhonghua Nei Ke Za Zhi. 42:643-5.
57. Zhang, Y., J. Li, Y. Zhan, et al. 2004. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect. Immun. 72:4410-5.